Gain Therapeutics Inc
NASDAQ:GANX
Gain Therapeutics Inc
Revenue
Gain Therapeutics Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Gain Therapeutics Inc
NASDAQ:GANX
|
Revenue
$55.2k
|
CAGR 3-Years
23%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$29.5B
|
CAGR 3-Years
5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
5%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
15%
|
CAGR 10-Years
19%
|
See Also
What is Gain Therapeutics Inc's Revenue?
Revenue
55.2k
USD
Based on the financial report for Dec 31, 2023, Gain Therapeutics Inc's Revenue amounts to 55.2k USD.
What is Gain Therapeutics Inc's Revenue growth rate?
Revenue CAGR 5Y
23%
Over the last year, the Revenue growth was -61%. The average annual Revenue growth rates for Gain Therapeutics Inc have been 23% over the past three years , 23% over the past five years .